Influence of selenium supplementation on lipid exchange in patients with metabolic-associated liver disease

Abstract

Background and Aims: Metabolic associated liver disease (MASLD) is often associated with dyslipidemia and oxidative stress, and can provoke hypertension (HTN) progression. Selenium performs various biological roles, especially protection against oxidative DNA damage caused by hydrogen peroxide and lipid hydroperoxide. Aim. Determine the therapeutic influence of sodium selenite on lipid exchange in patients with SLD and concomitant HTN. Methods: The study included: main group — 49 patients with MASLD and HTN; comparison group — 51 patients with isolated MASLD. The median age was 51.0 [45.0; 56.0] years (р1-3 = 0.980) and 52.0 [47.0; 54.0] years (р1-2 =0.610) respectively. Levels of total cholesterol (TC), triglycerides (TG), high-density lipoproteins (HDL), low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL) were determined by enzymatic colorimetric method. Selenium levels were measured by immunoassays (ELISA Kit). IBM SPSS 25.0 for Windows was used for statistical calculations. Results: Median BMI in all study groups corresponded to normal or increased body weight. Additionally, to standard MASLD treatment, 22 patients of the main group and 29 patients of the comparison group were prescribed 300 μg/day of sodium selenite during the first 14 days, followed by a maintenance dose of 100 μg/day for the next 2 months. Model for predicting the comorbid course of MASLD and HTN were calculated too. The studied parameters are listed in Table 1, table 2 and figure 1. Conclusions: According calculated model, it can be assumed that changes in VLDL and selenium levels can lead to a higher risk of developing concomitant HTN in patients with MASLD. Adding selenium-containing drugs to standard MASLD treatment recommendations, especially in patients with concomitant HTN, can reliably improve outcomes, which is a compelling direction for further researches.